Highlights

  • Infratil (ASX:IFT) has significant exposure to CDC Data Centres, which has become one of the largest contributors to portfolio value.
  • CDC's signed capacity exceeds 1 gigawatt, supported by major long-term customer contracts and a development pipeline targeting 3.9 gigawatts by 2040.
  • CDC's EBITDAF is expected to increase materially in FY27, but the scale of its expansion brings funding, execution and concentration risks.
  • Investors will be watching valuation updates, customer contracting, funding requirements and whether data-centre Demand keeps pace with planned capacity.

Infratil (ASX:IFT) has increasingly become associated with the growth of CDC Data Centres, an asset that has delivered substantial portfolio value creation while also increasing the group's exposure to a single sector. The debate is no longer simply about whether data-centre demand is growing, but whether the scale of investment, funding requirements and valuation assumptions can remain justified as the global AI-infrastructure cycle evolves.

The catalyst: a company defending its crown jewel

Infratil's Leadership has been working to reassure investors about the group's heavy exposure to CDC Data Centres, the Australasian operator that has become both a major driver of portfolio value and an increasingly important source of concentration risk.

The concern is not centred on whether CDC is growing. Its contracted capacity, customer pipeline and Earnings trajectory all point to expansion.

Instead, investors are focused on how much of Infratil's portfolio value is now tied to CDC, how that value is determined, and whether the broader build-out of AI and cloud infrastructure could eventually outpace underlying demand.

For Infratil (ASX:IFT), the challenge is therefore to demonstrate that CDC's expansion remains contracted, disciplined and fundable rather than dependent on speculative future demand.

How CDC came to dominate the story

CDC is no longer simply one asset within the portfolio.

At 30 June 2026, CDC was independently valued at a midpoint of about A$18.5 billion, equivalent to roughly NZ$22.5 billion, up 23.6% from the March quarter.

Infratil's approximately 49.7% stake was valued at around A$9.21 billion, or NZ$11.2 billion, representing an increase of about A$1.76 billion in one quarter.

Based on portfolio estimates, CDC accounts for roughly 40% of Infratil's total portfolio value, making the company increasingly exposed to data-centre demand and valuation movements.

Operational momentum has supported that increase. In May, CDC signed a 555-megawatt contract with a US hyperscaler, described as the largest data-centre contract signed in Australia.

The 10-year agreement, with renewal options, lifted CDC's contracted capacity and reinforced the view that a significant portion of planned expansion is supported by customer commitments.

CDC's signed capacity now exceeds 1 gigawatt, while its development pipeline target has been expanded to 3.9 gigawatts by 2040. The new pipeline alone is expected to require roughly A$20 billion of capital expenditure.

The financials — and the funding question

The earnings trajectory helps explain why CDC has become such a central part of Infratil's Investment case.

CDC generated around A$393 million of EBITDAF in FY26, with guidance indicating approximately A$680–720 million in FY27. Management is targeting more than A$1 billion of EBITDAF by FY28 on a 100%-of-CDC basis.

Infratil's full-year result to 31 March 2026 was supported by CDC and US renewables developer Longroad Energy, highlighting the increasing importance of growth infrastructure within the portfolio.

However, expansion at this scale requires substantial funding.

CDC's build-out has been supported by significant Equity and debt, including A$1.7 billion in hybrid and senior bonds and a US$400 million private placement. The operator carries a Moody's Baa2 Credit rating.

Infratil has also contributed additional equity to CDC over time and has previously raised capital from shareholders to support portfolio investment.

The key question is whether future development can increasingly be funded through CDC's own Balance Sheet and Debt capacity rather than requiring repeated equity injections from Infratil.

What is driving the nervousness

Three issues sit at the centre of investor caution.

First is concentration. With around 40% of portfolio value linked to CDC, Infratil's valuation is increasingly influenced by the performance of a single asset class.

Large customer contracts also create some concentration risk because a relatively small number of hyperscale customers can represent substantial portions of future demand.

Second is valuation methodology. CDC's value is determined through independent valuation processes using discounted Cash Flow assumptions and a blended cost of equity rather than through a continuously traded market price.

That means changes in discount rates, expected demand, pricing assumptions or Capital Expenditure requirements can materially affect portfolio value even without an immediate change in operating performance.

Third is the broader data-centre investment cycle. Global hyperscalers are committing substantial amounts of capital to artificial intelligence infrastructure, raising concerns that capacity growth could eventually exceed demand.

If that occurred, data-centre utilisation, pricing and long-term valuation assumptions could come under pressure.

The growth story beyond CDC

Management's response to concentration concerns rests partly on the argument that CDC's expansion is supported by signed customer demand rather than speculative construction.

The 555MW hyperscaler agreement and more than 1GW of signed capacity provide evidence that a substantial portion of future growth is linked to committed customer requirements.

The second argument is that Infratil remains diversified beyond CDC.

One NZ remains an important portfolio company and a major earnings contributor, with FY26 EBITDA guidance of NZ$595–625 million.

Longroad Energy is expanding its US renewable-energy platform and is targeting approximately 9 gigawatts of capacity by 2029.

The portfolio also includes RetireAustralia, UK data-centre operator Kao Data and diagnostic-imaging group Qscan.

This Diversification provides some counterbalance to CDC, although the increasing value of the data-centre Business means its influence on overall portfolio returns remains substantial.

The risks

The risks largely mirror the factors supporting the growth case.

A slowdown in AI-related capital expenditure or excess data-centre Supply could affect both CDC's earnings outlook and the assumptions used in its independent valuation.

Customer concentration creates additional counterparty and renewal risks, particularly where large contracts represent substantial increments of capacity.

The scale of the development program also creates execution risk. Large infrastructure projects can face delays, cost Inflation and commissioning challenges, all of which could affect expected returns.

Funding remains another important consideration. Rising debt levels and large capital requirements could reduce financial flexibility if interest rates or credit-market conditions become less favourable.

Infratil also carries regulatory, currency and operational exposure across Australia, New Zealand, the United States and the United Kingdom.

Finally, valuation remains an inherent risk. A portfolio containing substantial independently valued Assets can experience significant changes in reported value when discount rates or demand assumptions are revised.

What Investors Should Watch Next

Investors should watch upcoming CDC valuation updates and any new customer contracts or reservations that convert into firm capacity.

These will provide the clearest evidence of whether customer demand is keeping pace with the planned build-out.

CDC's progress toward FY27 EBITDAF guidance of A$680–720 million will also be important, alongside any additional debt or equity funding announcements.

Infratil's future results and investor commentary will provide further insight into portfolio concentration, capital allocation and the extent to which growth at CDC can be funded independently.

Any signs of contract delays, pricing pressure or weaker utilisation expectations would Warrant closer attention.

The Bottom Line

Infratil (ASX:IFT) has benefited materially from CDC Data Centres, with contracted capacity, rising earnings expectations and a large development pipeline supporting the asset's growing importance within the portfolio.

However, that success has also increased concentration risk and made Infratil more sensitive to data-centre valuation assumptions, funding requirements and the broader AI-infrastructure cycle.

The central investment question is whether CDC can continue converting contracted demand into earnings growth while funding its expansion without placing excessive pressure on Infratil's balance sheet.

For investors, the focus should remain on customer commitments, valuation discipline, development execution and whether demand continues to justify the scale of planned capacity.